Latest From Qiagen NV
The US National Institutes of Health and the Biomedical Advanced Research and Development Authority are asking manufacturers to provide new COVID-19 diagnostic candidates for NIH’s Rapid Acceleration of Diagnostics (RADx) program.
The US government’s Biomedical Advanced Research and Development Authority has awarded Nanomix up to $570,000 to develop a SARS-CoV-2 test for its portable, rapid Nanomix eLab analyzer.
Germany has ramped up its COVID-19 testing capacity to 260,000 per week, and still has a relatively low death rate from the virus. The country's diagnostics industry says it is ready to play its part “24/7.”
Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz.
Drug Discovery Tools
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Qiagen NV
- Senior Management
Thierry Bernard, Interim CEO
Roland Sackers, CFO
Manuel O Mendez, SVP, Global Commercial Operations
Barthold Piening, PhD, SVP, Head of Global Operations
- Contact Info
Phone: (31) 77 3556600
Venlo, 5912 PL